YS logo

YS Biopharma Co (YS) Stock

Profile

Full Name:

LakeShore Biopharma Co., Ltd

Sector:

Healthcare

Industry:

Biotechnology

Country:

China

IPO:

05 August 2021

Indexes:

Not included

Website:

http://www.ysbiopharm.com

Description:

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$100.37 M(+28.20% YoY)

Annual EPS

-$0.44(-11.31% YoY)

PE Ratio

-

Annual ROE

-20.07%

Annual Debt To Equity

0.67

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 15, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

13 Nov '23 Noble Capital Markets
Outperform

Screeners with YS included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$13.00
YS price is currently at an all-time high

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

+164.6%
YS annual revenue is up +164.6% over the past 3 years

Annual Revenue Estimate

$82.30 M
YS annual revenue is currently +21.96% higher than the consensus analysts' forecast

Annual Net Income 3-Year Change

+24.95%
YS annual net profit is up +24.95% over the past 3 years

Annual EPS 3-Year Change

-33.28%
YS annual earnings per share is down -33.28% over the past 3 years

Annual EPS Estimate

-$0.45
YS annual earnings per share is currently -1.13% lower than the consensus analysts' forecast

Annual Gross Profit

$77.97 M
YS annual gross profit is $77.97 million

Annual Operating Profit

-$16.55 M
YS annual operaing income is -$16.55 million

Annual Operating Profit 3-Year Change

+8.33%
YS annual operaing income is up +8.33% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-20.07%
YS annual return on equity is -20.07%

Annual ROA

-8.92%
YS annual return on assets is -8.92%

Annual EBIT

-$16.58 M
YS annual earnings before interest & taxes is -$16.58 million

Annual EBITDA

-$11.22 M
YS annual earnings before interest, taxes, depreciation & amortization is -$11.22 million

Annual Interest Coverage Ratio

-3.68
YS annual interest coverage ratio is -3.68

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

1.29
YS annual quick ratio is 1.29

Annual Current Ratio

1.57
YS annual current ratio is 1.57

Annual Total Assets

$249.90 M
YS annual total assets is $249.90 million

Annual Current Assets

$150.54 M
YS annual total current assets is $150.54 million

Annual Total Liabilities

$144.04 M
YS annual total liabilities is $144.04 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+26.78%
YS annual cash flow from operations is up +26.78% over the past 3 years

Annual CFI 3-Year Change

+45.9%
YS annual cash flow from investing activities is up +45.9% over the past 3 years

Annual CFF 3-Year Change

-57.5%
YS annual cash flow from financing activities is down -57.5% over the past 3 years

Annual CAPEX

$8.33 M
YS annual capital expenditures is $8.33 million

Annual CAPEX 3-Year Change

-46.17%
YS annual capital expenditures is down -46.17% over the past 3 years

Annual FCF

-$34.98 M
YS annual free cash flow is -$34.98 million

Annual FCF 3-Year Change

+32.57%
YS annual free cash flow is up +32.57% over the past 3 years

Institutional Ownership

Similar stocks

YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS
Seeking Alpha19 April 2024

YS Biopharma Co., Ltd. (NASDAQ:YS ) Q3 2024 Earnings Conference Call on April 19, 2024 at 8:00 AM ET. Company Participants include Alyssa Li - Director of Investor Relations, David Shao - President & CEO, Zenaida Mojares - Chief Medical Officer, Brenda Wu - CFO. Conference Call Participants include Hunter Diamond from Diamond Equity Research. Operator thanks everyone for joining YS Biopharma's Earnings Call for the First Nine Months of Fiscal Year 2024.

Why Is YS Biopharma (YS) Stock Up 71% Today?
Why Is YS Biopharma (YS) Stock Up 71% Today?
Why Is YS Biopharma (YS) Stock Up 71% Today?
YS
InvestorPlace25 August 2023

YS Biopharma (NASDAQ: YS ) stock is rising higher on Friday after the biopharmaceutical company announced officers purchasing shares. According to a press release, the company's founder and chairperson, Yi Zhang, as well as its director, president and CEO Hui Shao, are behind the share purchase.

Why Is YS Biopharma (YS) Stock Up 71% Today?
Why Is YS Biopharma (YS) Stock Up 71% Today?
Why Is YS Biopharma (YS) Stock Up 71% Today?
YS
InvestorPlace25 August 2023

YS Biopharma (NASDAQ: YS ) stock is rising higher on Friday after the biopharmaceutical company announced officers purchasing shares. According to a press release, the company's founder and chairperson, Yi Zhang, as well as its director, president and CEO Hui Shao, are behind the share purchase.

Why Is YS Biopharma (YS) Stock Up 31% Today?
Why Is YS Biopharma (YS) Stock Up 31% Today?
Why Is YS Biopharma (YS) Stock Up 31% Today?
YS
InvestorPlace13 June 2023

YS Biopharma (NASDAQ: YS ) stock is on the rise Tuesday as investors await positive news from a conference taking place today. This is the Global Select Spotlight Emerging Growth Invitational Investor Conference.

FAQ

  • What is the primary business of YS Biopharma Co?
  • What is the ticker symbol for YS Biopharma Co?
  • Does YS Biopharma Co pay dividends?
  • What sector is YS Biopharma Co in?
  • What industry is YS Biopharma Co in?
  • What country is YS Biopharma Co based in?
  • When did YS Biopharma Co go public?
  • Is YS Biopharma Co in the S&P 500?
  • Is YS Biopharma Co in the NASDAQ 100?
  • Is YS Biopharma Co in the Dow Jones?
  • When was YS Biopharma Co's last earnings report?
  • When does YS Biopharma Co report earnings?

What is the primary business of YS Biopharma Co?

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

What is the ticker symbol for YS Biopharma Co?

The ticker symbol for YS Biopharma Co is NASDAQ:YS

Does YS Biopharma Co pay dividends?

No, YS Biopharma Co does not pay dividends

What sector is YS Biopharma Co in?

YS Biopharma Co is in the Healthcare sector

What industry is YS Biopharma Co in?

YS Biopharma Co is in the Biotechnology industry

What country is YS Biopharma Co based in?

YS Biopharma Co is headquartered in China

When did YS Biopharma Co go public?

YS Biopharma Co's initial public offering (IPO) was on 05 August 2021

Is YS Biopharma Co in the S&P 500?

No, YS Biopharma Co is not included in the S&P 500 index

Is YS Biopharma Co in the NASDAQ 100?

No, YS Biopharma Co is not included in the NASDAQ 100 index

Is YS Biopharma Co in the Dow Jones?

No, YS Biopharma Co is not included in the Dow Jones index

When was YS Biopharma Co's last earnings report?

YS Biopharma Co's most recent earnings report was on 15 August 2024

When does YS Biopharma Co report earnings?

The date for YS Biopharma Co's next earnings report has not been announced yet